公开(公告)号：US20230330244A1

公开(公告)日：2023-10-19

申请号：US18014890

申请日：2021-07-12

Applicant: Ontario Institute for Cancer Research (OICR)

Inventor： Ahmed Mamai

IPC: A61K47/68 ,  C07D401/12 ,  C07D213/55

CPC classification number: A61K47/6803 ,  A61K47/6849 ,  C07D401/12 ,  C07D213/55 ,  A61K47/6851 ,  C07B2200/05

Abstract: The present application relates to nicotinamide phosphoribosyltransferase (NAMPT) inhibitor-linker conjugates of Formula (I) comprising NAMPT inhibitors linked to linker groups, to processes and intermediates for their preparation, and to compositions comprising these compounds, as well as their use, for example, in the treatment or diagnosis of diseases and conditions, including, but not limited to, cancer. (I)

公开(公告)号：US11505539B2

公开(公告)日：2022-11-22

申请号：US16955998

申请日：2018-12-21

Applicant: Ontario Institute for Cancer Research (OICR)

Inventor： Methvin Isaac ,  Anh My Chau ,  Ahmed Mamai

IPC: C07D401/14 ,  A61K31/506 ,  A61P35/02 ,  A61K45/06

Abstract: The present application relates to compounds of Formula I (I) or pharmaceutically acceptable salts, solvates and/or prodrugs thereof, to compositions comprising these compounds or pharmaceutically acceptable salts, solvates and/or prodrugs thereof, and various uses in the treatment of diseases, disorders or conditions that are treatable by inhibiting interactions with BCL6 BTB and/or by degrading BCL6, such as cancer.

公开(公告)号：US11242351B2

公开(公告)日：2022-02-08

申请号：US16955975

申请日：2018-12-21

Applicant: Ontario Institute for Cancer Research (OICR)

Inventor： Rima Al-awar ,  Methvin Isaac ,  Anh My Chau ,  Ahmed Mamai ,  Iain Watson ,  Gennady Poda ,  Pandiaraju Subramanian ,  Brian Wilson ,  David Uehling

IPC: C07D487/04 ,  A61K31/519 ,  C07D487/14 ,  A61P35/04 ,  C07D471/14 ,  C07D498/14 ,  C07D519/00

Abstract: The present application relates to compounds of Formula (I) or pharmaceutically acceptable salts, solvates and/or prodrugs thereof, to compositions comprising these compounds or pharmaceutically acceptable salts, solvates and/or prodrugs thereof, and various uses in the treatment of diseases, disorders or conditions that are treatable by inhibiting interactions with BCL6 BTB, such as cancer.

公开(公告)号：US20210106694A1

公开(公告)日：2021-04-15

申请号：US16956021

申请日：2018-12-20

Applicant: Ontario Institute for Cancer Research (OICR)

Inventor： Rima Al-awar ,  Ahmed Mamai

IPC: A61K47/68 ,  C07D311/68 ,  C07D215/42 ,  C07D335/06 ,  C07D223/16 ,  A61K38/07 ,  C07D498/18 ,  A61K45/06 ,  A61P35/00

Abstract: The present application is directed to compounds of Formula (I): compounds of Formula (II): compounds of Formula (III): and compounds of Formula (IV): compositions comprising these compounds and their uses, for example as medicaments and/or diagnostics. Specifically claimed are: (1) compounds containing reactive functional groups (compound of formula I), compounds containing compounds to be linked together (compound of formula II) and compounds having a reactive functional group/a compound to be linked (compound of formula IV), (2) an antibody-drug conjugate (compound of formula III), wherein the antibody is covalently attached by a linker to one or more drugs, (3) pharmaceutical compositions comprising compounds of Formula (II) or Formula (III), (4) treatment/diagnosis of disease comprising compounds of Formula (II) or Formula (III), and (5) methods of preparing an ADC of Formula III.

公开(公告)号：US20190112672A1

公开(公告)日：2019-04-18

申请号：US16306724

申请日：2017-06-02

Applicant: ONTARIO INSTITUTE FOR CANCER RESEARCH (OICR) ,  UNIVERSITY HEALTH NETWORK

Inventor： Julia A. Hopkins ,  Paul Boutros ,  Robert G. Bristow

IPC: C12Q1/6886 ,  G16H50/20 ,  G16H50/30 ,  C12Q1/6881

Abstract: There is described herein a method of prognosing and/or predicting disease progression and/or in subject with prostate cancer, the method comprising: a) providing a sample containing mitochondrial genetic material from prostate cancer cells; b) sequencing the mitochondrial genetic material with respect to at least 1 patient biomarker selected from CSB1, OHR, ATP8 and HV1 (hypervariable region 1); c) comparing the sequence of said patient biomarkers to control or reference biomarkers to determine mitochondrial single nucleotide variations (mtSNVs); and d) determining the a prostate cancer prognosis; wherein a relatively worse outcome is associated with the presence of mtSNVs in CSB1, OHR, ATP8 and a relatively better outcome is associated with the presence of mtSNVs in HV1.

公开(公告)号：US20240317723A1

公开(公告)日：2024-09-26

申请号：US18288219

申请日：2022-05-02

Applicant: Ontario Institute for Cancer Research (OICR)

Inventor： Rima Al-Awar ,  Methvin Isaac ,  Babu Joseph ,  Radek Laufer ,  Ganna Posternak ,  Michael Prakesch ,  David Uehling ,  Iain Watson ,  Brian Wilson ,  Carlos Armando Zepeda-Velazquez ,  Anh Chau ,  Tao Xin

IPC: C07D405/14 ,  A61K31/497 ,  A61K31/517 ,  A61K31/5377 ,  A61P35/00 ,  C07D401/04 ,  C07D403/04 ,  C07D413/14

CPC classification number: C07D405/14 ,  A61K31/497 ,  A61K31/517 ,  A61K31/5377 ,  A61P35/00 ,  C07D401/04 ,  C07D403/04 ,  C07D413/14

Abstract: The present application relates to substituted amino aza-heteroaryl compounds of Formula (I) and substituted aza-heteroaryl compounds of Formula II or pharmaceutically acceptable salts, solvates and/or prodrugs thereof, to compositions comprising these compounds or pharmaceutically acceptable salts, solvates and/or prodrugs thereof, and various uses in the treatment of diseases, disorders or conditions that are treatable by inhibiting HPK1, such as cancer.

公开(公告)号：US20240092763A1

公开(公告)日：2024-03-21

申请号：US18271103

申请日：2022-01-07

Applicant: Ontario Institute for Cancer Research (OICR) ,  The Governing Council of The University of Toronto ,  Sinai Health System

Inventor： Rima Al-Awar ,  Liliana Attisano ,  Methvin Isaac ,  Yong Liu ,  David Smil ,  David Uehling ,  Jeff Wrana

IPC: C07D403/14 ,  A61P35/00 ,  C07D401/14 ,  C07D403/12 ,  C07D471/10 ,  C07D487/04 ,  C07D487/08

CPC classification number: C07D403/14 ,  A61P35/00 ,  C07D401/14 ,  C07D403/12 ,  C07D471/10 ,  C07D487/04 ,  C07D487/08

Abstract: The present application relates to compounds of Formula (I) or pharmaceutically acceptable salts, solvates and/or prodrugs thereof, to compositions comprising these compounds or pharmaceutically acceptable salts, solvates and/or prodrugs thereof, and various uses in the treatment of diseases, disorders or conditions that are treatable by inhibiting or blocking NUAK kinase, such as cancers and fibrosis.

公开(公告)号：US11192880B2

公开(公告)日：2021-12-07

申请号：US16955951

申请日：2018-12-20

Applicant: Ontario Institute for Cancer Research (OICR)

Inventor： Methvin Isaac ,  Anh My Chau

IPC: C07D401/14 ,  A61K31/506 ,  C07D413/14 ,  C07D471/08

Abstract: The present application relates to compounds of Formula I or pharmaceutically acceptable salts, solvates and/or prodrugs thereof, to compositions comprising these compounds or pharmaceutically acceptable salts, solvates and/or prodrugs thereof, and various uses in the treatment of diseases, disorders or conditions that are treatable by inhibiting interactions with BCL6 BTB and/or by degrading BCL6, such as cancer.

公开(公告)号：US20210053978A1

公开(公告)日：2021-02-25

申请号：US16955975

申请日：2018-12-21

Applicant: Ontario Institute for Cancer Research (OICR)

Inventor： Rima Al-awar ,  Methvin Isaac ,  Anh My Chau ,  Ahmed Mamai ,  Iain Watson ,  Gennady Poda ,  Pandiaraju Subramanian ,  Brian Wilson ,  David Uehling

IPC: C07D487/14 ,  C07D471/14 ,  C07D519/00 ,  C07D498/14 ,  A61P35/04

Abstract: The present application relates to compounds of Formula (I) or pharmaceutically acceptable salts, solvates and/or prodrugs thereof, to compositions comprising these compounds or pharmaceutically acceptable salts, solvates and/or prodrugs thereof, and various uses in the treatment of diseases, disorders or conditions that are treatable by inhibiting interactions with BCL6 BTB, such as cancer.

公开(公告)号：US20200331921A1

公开(公告)日：2020-10-22

申请号：US16960924

申请日：2019-02-06

Applicant: Ontario Institute for Cancer Research (OICR)

Inventor： Rima Al-awar ,  Methvin Isaac ,  Anh My Chau ,  Ahmed Mamai ,  Lain Watson ,  Gennady Poda ,  Pandiaraju Subramanian ,  Brian Wilson ,  David Uehling ,  Michael Prakesch ,  Babu Joseph ,  Justin-Alexander Morin

IPC: C07D487/04 ,  C07D519/00 ,  C07D471/04

Abstract: The present application relates to compounds of Formula I (I) or pharmaceutically acceptable salts, solvates and/or prodrugs thereof, to compositions comprising these compounds or pharmaceutically acceptable salts, solvates and/or prodrugs thereof, and various uses in the treatment of diseases, disorders or conditions that are treatable by inhibiting interactions with BCL6 BTB, such as cancer.